Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun:57:113-117.
doi: 10.1016/j.breast.2021.03.008. Epub 2021 Mar 25.

The applicability of Magseed® for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy

R Reitsamer  1 , F Peintinger  2 , E Forsthuber  3 , A Sir  3
Affiliations

The applicability of Magseed® for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy

R Reitsamer et al. Breast. 2021 Jun.

Abstract

Background: Targeted axillary dissection (TAD), the combination of sentinel lymph node biopsy (SLNB) and targeted lymph node biopsy (TLNB), can reduce the false negative rates of sentinel node biopsy alone dramatically in breast cancer patients, who received neoadjuvant chemotherapy (NAC). However methods for TAD are still under investigation.

Methods: Magseed®, a non-radioactive magnetic marker was used to mark the biopsied positive TLN after NAC. The SLNB with the standard technetium-based method and the selective TLNB with Magseed® localization were performed in 40 patients. The TLNs were identified with the Sentimag® probe and excised in all patients. Specimen x-ray was performed to confirm the Magseed® within the prior to NAC biopsied and clipped lymph node.

Results: The TLN identification rate was 100% (40/40), the SLN identification rate was 82.5% (33/40), the concordance rate between the TLN and the SLN was 65% (26/40). Complications according Magseed® deployment or identification could not be observed.

Conclusion: Magseed® is a reliable and feasible marker for the identification of TLNs after NAC.

Keywords: Magnetic marker; Targeted axillary dissection; Targeted lymph node biopsy.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest None of the authors has to disclose any commercial interest in the subject of the study, and there was no financial or material support.

Figures

Fig. 1
Fig. 1
One Magseed® marks one clipped lymph node.
Fig. 2
Fig. 2
One Magseed® marks two clipped lymph nodes.
Fig. 3
Fig. 3
Two Magseed®s mark two clipped lymph nodes.
Fig. 4
Fig. 4
Extinction artefact of Magseed® in the MRI.
See this image and copyright information in PMC

References

    1. Boughey J.C., Suman V.J., Mittendorf E.A. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. J Am Med Assoc. 2013;310(14):1455–1461. - PMC - PubMed
    1. Kuehn T., Bauerfeind I., Fehm T. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–618. - PubMed
    1. Boileau J.F., Poirier B., Basik M. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258–264. - PubMed
    1. Caudle A.S., Yang W.T., Krishnamurthy S., Mittendorf E.A., Black D.M. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072–1078. - PMC - PubMed
    1. Donker M., Straver M.E., Wesseling J. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261(2):378–382. - PubMed

MeSH terms

Substances